Demonstrating the usefulness and complications of multiagent intravitreal chemotherapy is necessary for successful treatment in patients with recalcitrant vitreous seeding of retinoblastoma.
I n the current era of retinoblastoma management, there are several alternatives for treatment of viable vitreous or subretinal tumor seeds, including intravenous, intra-arterial, subtenon, or intravitreal chemotherapy, as well as enucleation or external beam radiotherapy. The choice of therapy is especially critical if the eye of concern is the only remaining eye of a young infant.
All eyes with extensive vitreous seeds are classified as group V by Reese-Ellsworth classification 1 or group D or E by the International Classification of Retinoblastoma. 2 Previous reports 3,4 investigating intravenous chemotherapy for retinoblastoma based on the Reese-Ellsworth classification have delineated success (globe salvage and avoidance of external beam radiotherapy) in 85% to 87% of groups I through IV and 36% to 47% of group V eyes. Success with intravenous chemotherapy, based on the International Classification of Retinoblastoma, was 90% to 100% for groups A, B, and C; 47% for group D; and 25% for group E. 5, 6 These results underscore the difficulty in vitreous seed control using intravenous chemotherapy.
Results for retinoblastoma control by intra-arterial chemotherapy have been somewhat more favorable for eyes with advanced disease, with globe salvage in 100% of group D and 33% of group E eyes. 7 Shields and associates 7 documented that intra-arterial chemotherapy can lead to complete control in 82% of subretinal seeds and 67% of vitreous seeds. In a similar study by Abramson and associates, 8 among treatmentnaive eyes, the 2-year probability of globe salvage in eyes with retinoblastoma and subretinal seeding was 83%; in vitreous seeding, 64%; and in eyes with both subretinal and vitreous seeding, 80%. Table 1 ). In the other 5 patients, who had recalcitrant vitreous seeds after systemic chemotherapy and multiple previous intravitreal melphalan, combined chemotherapy (melphalan and topotecan) was administered. Both drugs were prepared in the operating room, where the patient was being examined while under general anesthesia. The drugs were reconstituted in a sterile fashion on a separate sterile tray by combination of the freeze-dried chemotherapy powder with dilu- ent provided by the manufacturers for melphalan and powder with balanced salt solution for topotecan. The initial dose of topotecan hydrochloride was 8 μg in the first patients; later dose escalation for improved vitreous seed control led to an adjustment up to 20 μg ( Table 2) . After preparation, the 2 medications were separately injected promptly through the pars plana (2.5 mm from the limbus, with a beveled approach) superotemporally using a 30-gauge needle. There was no aqueous humor tap to soften the globe. Cryotherapy at the injection site was performed during needle withdrawal as a single freeze-thaw cycle. Globe "jiggling" to disperse chemotherapy within the eye was performed for 10 seconds. An antibiotic and corticosteroid preparation was applied to the eye after the injection. There was no eye patch or medication prescribed postoperatively. To prevent infection, the family was instructed to not manipulate the eye. 9 Intraocular pressure was monitored 30 minutes after injection and at each follow-up. Patient examination was performed every 2 weeks under general anesthesia, with repeated injection if needed at the time of general anesthesia until complete vitreous seed control was achieved. Success was defined as complete regression of vitreous seeds clinically. Failure, independent of eyes undergoing enucleation, was defined as vitreous seed nonresponse, increase in the amount of vitreous seeds, and/or the appearance of new vitreous seeds noted on ophthalmoscopic examination.
Results
During the past 2 years, 9 eyes of 9 patients received combination IVC with melphalan and topotecan for viable vitreous seeds from retinoblastoma ( Table 2 ). All 9 patients had received 6 cycles of standard chemotherapy (vincristine sulfate, etoposide, and carboplatin). In addition, 1 patient received external beam radiotherapy and 5 received intraarterial chemotherapy for tumor and seed control. Four of the 9 patients had previously undergone enucleation of the opposite eye for advanced retinoblastoma. At the time of intravitreal injection, no patient was receiving systemic chemotherapy.
The intravitreal injection was uncomplicated in every case. A total of 40 injections were given through the pars plana. There were no immediate or delayed complications of vitreous hemorrhage, retinal detachment, endophthalmitis, or cataract. At 30 minutes following the injection and at the 2-week follow-up, intraocular pressure was 22 mm Hg or less. There were 2 cases of hypotony (intraocular pressure decreased to 8 mm Hg), lasting for 2 weeks. One of those eyes was later enucleated.
Success with complete control of vitreous seeds was achieved in all 9 cases (100%) with a mean of 1.9 injections of topotecan and melphalan (median, 2; range, 1-3 injections) (Figure) . In 3 cases (33%), tumor control was achieved with a single injection, whereas in 6 (67%) cases, 2 or 3 injections were necessary. In case 9, an 8-μg dose of topotecan hydrochloride was used for 2 sessions, but it was not effective, and the dosage was increased to 20 μg. Five of the 9 eyes (56%) had received previous intravitreal monotherapy with melphalan for a mean of 4.6 injections (median, 5; range, 2-8 injections) without significant response to treatment before the decision of combined IVC was made.
In 3 patients (33%) enucleation was performed: 1 with anterior segment retinoblastoma and the other 2 with recurrent intraretinal tumor near previously regressed retinoblastoma after both intravenous and intra-arterial chemotherapy. The pathology reports showed the active tumor on the iris and ciliary body in one patient, with adjacent vitreous involvement and the active tumor in the retina with a small amount of vitreous seeds near the new lesion.
Complications with doses of topotecan hydrochloride, 8 to 20 μg, and melphalan hydrochloride, 40 μg, were mild, including temporary hypotonia in 2 patients for 2 weeks, epithelial defect in 1 patient lasting 1 week, and a mild vitreous hemorrhage in 1 patient. There were no a-and b-wave changes in the bright-flash electroretinogram in our patients. In addition, there was no subconjunctival, orbital, or metastatic retinoblastoma during a mean of 15.2 months follow-up (median, 16; range, 7-25 months).
Discussion
Viable retinoblastoma seeding into the vitreous after intravenous or intra-arterial chemotherapy has been a major obstacle to globe salvage. The use of IVC has greatly reduced the negative impact of vitreous seed residual and improved the prognosis for globe retention. Intravitreal chemotherapy was first explored by Ericson and Rosengren in 1961. 14 Intravitreal injection of melphalan hydrochloride, 8 to 30 μg, combined with ocular hyperthermia was promoted by Suzuki and Kaneko, 27 who showed promising results with nearly 51% success. Munier and associates 9 explored intravitreal melphalan hydrochloride, 8 to 30 μg, in 23 patients with recurrent retinoblastoma vitreous seeds, using up to 8 weekly injections, and achieved 87% control at 22 months. Ghassemi and Shields 11 studied 12 children facing enucleation for viable persistent or recurrent vitreous seeds following systemic chemotherapy. Eight eyes treated with 8 to 10 μg of melphalan hydrochloride showed partial control at 71% short-term and 43% long-term follow-up, with minor local toxic effects. In that study, 4 eyes received 50-μg doses, with 100% control in short-and long-term follow-up, but with serious adverse local effects of hypotonia and/or phthisis bulbi in some cases. More recently, Shields and associates 28 reported 100%
control of retinoblastoma vitreous seeds in 11 additional cases, with minimal toxic effects, using a mean of 5 injections of melphalan hydrochloride, 20 to 30 μg. In the present study, retinoblastoma vitreous seed control was achieved in 100% of 9 eyes, using 40 μg of melphalan hydrochloride and 8 to 20 μg of topotecan hydrochloride, but with a much shorter course (median, 1 injection). The rapidity and duration of control with the single injection of 2 medications, with minimal toxic effects, were remarkable. Topotecan displays excellent antitumor activity for retinoblastoma and relatively low ocular toxic effects. 26 In a study After injection of 0.5 mg/0.1 mL, maximum concentrations in the vitreous were 709.0 ng/mL and 695.4 ng/L, as lactone and total topotecan, respectively. Vitreous levels above a potentially therapeutic threshold of 14.0 ng/mL were obtained for lactone topotecan up to 5.5 hours after intravitreal injection. 29 This pharmacokinetic study showed that topotecan elimination half-life in the vitreous was 2.5 hours after a 5-mg dose; thus, if the drug is administered in a weekly fashion no accumulation should be expected. Initially, our group attempted monotherapy using melphalan, but later failures led to exploration of combined therapy. Our first few cases demonstrated immediate seed control, leading to our desire to use combination therapy as a first choice for vitreous seeds. We suspect that a relative chemotherapy resistance to melphalan, in some cases, could be overcome with topotecan rescue.
We believe that concomitant sterilization of the needle tract using cryotherapy has increased the safety profile of this technique. Munier and coworkers 9 administered a total of 135 intravitreal injections for retinoblastoma vitreous seeding (melphalan hydrochloride [n = 124], carboplatin [n = 2], and ranibizumab [n = 9]) and found no case of orbital seeding. In a previous series, 11 33 injections were administered with no sign of orbital seeding. Shields and associates 28 additionally reported a total of 55 injections for vitreous seeds with no orbital seeding.
In the present study, a total of 17 combined sessions of intravitreal injections using combined melphalan and topotecan were given for complete response of vitreous seeds in 100% of eyes with minimal toxic effects. Previous protocols 9, 11, 28 called for 6 or 8 injections of melphalan. In this series, we achieved vitreous seed control with a median of 2 injections (mean, 1.9), which is notably fewer than in previous studies. An additional finding in this study was that eyes with previous failure following intravitreal administration of melphalan showed a complete response to injection of the melphalan and topotecan combination.
Conclusions
Our 2-year experience with combined intravitreal injection of melphalan and topotecan for recurrent or recalcitrant vitreous retinoblastoma seeds has demonstrated seed control among eyes not subsequently enucleated, although the longterm visual outcome remains to be determined. This approach should be considered in children with retinoblastoma and vitreous seeding who do not respond to standard measures of intravenous or intra-arterial chemotherapy.
